Quest Diagnostics Incorporated(DGX)

New York Stock Exchange
Sector: Healthcare | Industry: Medical - Diagnostics & Research
Quest Diagnostics Incorporated logo

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Latest News & Analysis

Medical diagnostic devices on a lab bench with abstract molecular forms in a purple-themed setting
Jul 16, 2025

Quest Diagnostics (DGX) Strategic Growth in Advanced Diagnostics and Financial Health Insights

Quest Diagnostics (DGX) advances in Alzheimer's, oncology, and infectious disease diagnostics, backed by solid financials and strategic acquisitions.

Read more →
Blood sample vial on a laboratory bench with scientific equipment and a soft purple background
Jul 11, 2025

Quest Diagnostics Inc (DGX) Advanced Diagnostics Growth Driven by FDA-Cleared Alzheimer's Test

Quest Diagnostics propels advanced diagnostics with FDA-cleared Alzheimer's blood test, boosting specialized testing revenue amid solid financial performance.

Read more →
Test tubes with colorful liquid on a lab bench surrounded by modern analysis equipment
Jul 10, 2025

Quest Diagnostics (DGX) Advances Alzheimer's Diagnostics, Strengthening Market Leadership

Quest Diagnostics expands into high-margin Alzheimer's and oncology diagnostics with FDA-cleared blood tests, driving strong Q2 earnings outlook and stock resilience.

Read more →
Medical laboratory equipment in a bright, modern lab with a purple-toned atmosphere
Jul 8, 2025

Quest Diagnostics (DGX) Q1 2025 Analysis: Advanced Diagnostics Drive Growth and Market Leadership

Quest Diagnostics' Q1 2025 growth is fueled by advanced diagnostics innovation, strategic acquisitions, and pioneering cancer and Alzheimer's tests, strengthening its market position.

Read more →
Scientist holding a blood sample vial in a laboratory with advanced equipment and a soft purple background
Jul 2, 2025

Quest Diagnostics (DGX) Advances Cancer and Alzheimer's Diagnostics with Strong Q1 Financials

Quest Diagnostics partners with MD Anderson for cancer blood test MCaST and launches AD-DETECT™ for Alzheimer's, showing robust Q1 2025 growth and strategic innovation.

Read more →
Laboratory blood test sample tube held by gloved hand in modern research facility
Jun 27, 2025

Quest Diagnostics (DGX): MCaST Blood Test Redefines Cancer Screening

Quest Diagnostics' MCaST blood test, developed with MD Anderson, marks a significant strategic pivot, aiming to redefine multi-cancer screening.

Read more →
Advanced medical diagnostic device in a modern laboratory with soft purple lighting
Jun 18, 2025

Quest Diagnostics (DGX): Strategic Pivot in Cancer Diagnostics

Quest Diagnostics is pioneering cancer diagnostics with its MD Anderson collaboration, aiming for early detection and robust financial growth.

Read more →
Modern laboratory test tubes and vials with blurred scientists and equipment in a purple-toned background
Jun 12, 2025

Quest Diagnostics (DGX): MD Anderson Collaboration & Q1 2025 Analysis

Quest Diagnostics' recent MD Anderson collaboration for a multi-cancer test signals a strategic pivot into high-growth oncology diagnostics.

Read more →
Quest Diagnostics' strategic growth in advanced cancer screening and women's health diagnostics, highlighting innovation and strong financial performance in healthcare.
Jun 11, 2025

Quest Diagnostics (DGX): Strategic Moves and Financial Snapshot

Quest Diagnostics' strategic moves in cancer and women's health diagnostics, coupled with recent financial performance, signal key shifts for investors.

Read more →
Quest Diagnostics: Innovations in Alzheimer's Testing, HPV Screening, and AI-Powered Diagnostics for Enhanced Public Health and Investment Opportunities
Apr 9, 2025

Quest Diagnostics (DGX): Innovation, AI, and Market Analysis

Quest Diagnostics (DGX) navigates market shifts with strategic innovation, AI integration, and expanding diagnostic services, despite a recent stock dip.

Read more →
Quest Diagnostics growth strategy: AI, partnerships, and acquisitions driving diagnostics innovation and shareholder value. DGX stock analysis.
Mar 25, 2025

Quest Diagnostics (DGX): AI, Partnerships, and the Future of Diagnostics

Quest Diagnostics (DGX) is strategically positioned for future growth through AI integration, expansion into early cancer detection, and strategic acquisitions.

Read more →
Quest Diagnostics strategic growth: Market access, advanced diagnostics, and AI integration drive DGX's sustainable growth and investor value.
Mar 19, 2025

Quest Diagnostics (DGX): Growth Strategy and Market Analysis

Quest Diagnostics is strategically positioned for growth through market expansion, advanced diagnostics, and partnerships, driving long-term shareholder value.

Read more →
Quest Diagnostics strategic moves: Fresenius acquisition, cancer diagnostics, and market analysis [DGX]
Mar 17, 2025

DGX Analysis: Quest Diagnostics' Growth Strategy and Market Position

Quest Diagnostics (DGX) is strategically expanding its diagnostic capabilities through acquisitions, partnerships, and innovation, positioning itself for future growth.

Read more →
Quest Diagnostics: Strategic acquisitions, cancer early detection, and Alzheimer's diagnostics driving growth in the diagnostic testing market. Stay informed on DGX stock.
Mar 6, 2025

Quest Diagnostics (DGX): Developments, Market Impact, and Outlook

Quest Diagnostics (DGX) navigates growth via strategic acquisitions and advanced diagnostics amidst debt management and healthcare policy shifts. Investor Day 2025 insights awaited.

Read more →
Quest Diagnostics: Strategic acquisitions, financial performance, and market outlook in diagnostic testing services. Stock analysis.
Feb 27, 2025

Quest Diagnostics (DGX): Strategic Acquisitions, Investor Day Preview, and Market Outlook

Quest Diagnostics (DGX) navigates strategic acquisitions, innovation, and an upcoming Investor Day, shaping its diagnostic leadership and market outlook.

Read more →
Quest Diagnostics strategic growth in diagnostics: acquisitions, cancer detection, and Alzheimer's testing. Investor Day 2025 preview.
Feb 26, 2025

Quest Diagnostics: Strategic Acquisitions, Cancer Detection, and Investor Day Preview

Quest Diagnostics expands through strategic acquisitions and partnerships, focusing on cancer and Alzheimer's diagnostics. Investor Day preview and financial analysis included.

Read more →
Quest Diagnostics: Strategic Expansion, Innovation, and Future Outlook - Exploring growth through acquisitions, partnerships (like Galleri cancer detection), and Alzheimer's diagnostics. Investor Day 2025 insights.
Feb 25, 2025

Quest Diagnostics: Strategic Expansion, Innovation, and Future Outlook

Quest Diagnostics strategically expands through acquisitions, partnerships, and innovation in Alzheimer's and cancer diagnostics. Investor Day 2025 promises insights into future strategies.

Read more →
Quest Diagnostics: Strategic acquisitions, cancer detection advancements, and detailed market analysis. Stay informed on DGX.
Feb 24, 2025

Quest Diagnostics: Strategic Acquisitions, Cancer Detection, and Market Outlook

Quest Diagnostics strategically expands with Spectra Laboratories acquisition and GRAIL partnership, innovating in Alzheimer's diagnostics. Investor Day insights awaited.

Read more →
Quest Diagnostics: Leading diagnostic innovation, strategic partnerships, and financial growth. Explore advancements in cancer detection, Alzheimer's diagnostics, and Q4 2024 financial performance. Invest in the future of healthcare.
Feb 21, 2025

Quest Diagnostics: Innovation and Leadership 2025

Comprehensive update on DGX's latest innovations, strategic partnerships, Q4 earnings, and market trends driving diagnostic growth.

Read more →
Quest Diagnostics: Analyzing market trends, innovation, and strategic partnerships for DGX stock growth.
Feb 21, 2025

Quest Diagnostics: Market Trends, Innovation, and Future Outlook

Quest Diagnostics navigates market dynamics with strategic collaborations and innovation, focusing on growth in diagnostics and Alzheimer's research.

Read more →